Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione

D Pessayre, M Tinel, D Larrey, B Cobert, C Funck-Brentano and G Babany

Troleandomycin, a macrolide antibiotic, has been shown to be demethylated and oxidized into a metabolite which forms an inactive complex with the iron(II) of cytochrome P-450. The role of glutathione in the metabolism of troleandomycin was investigated. Administration of troleandomycin (1 mmol X kg-1 p.o.) decreased the concentration of glutathione in the liver. The depletion of glutathione was increased in rats pretreated with phenobarbital and decreased in rats pretreated with CoCl2. In vitro, an inverse relationship was found between the concentration of glutathione in the incubation mixture and the appearance of the cytochrome P-450-troleandomycin metabolite complex. Glutathione, however, did not inhibit the demethylation of troleandomycin and did not destroy the cytochrome P-450-troleandomycin metabolite complex. The in vitro protective effect of glutathione was reproduced by cysteine but not by glycine. In vivo, decreasing the concentration of glutathione in the liver by food deprivation or by the administration of diethylmaleate increased the formation of the cytochrome P-450-troleandomycin metabolite complex. These results indicate that glutathione is depleted by a troleandomycin metabolite in vivo, whereas glutathione protects against the formation of the inactive cytochrome P-450-troleandomycin metabolite complex in vitro and in vivo.

Volume 224, Issue 3, pp. 685-691, 03/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. Tietz, M. H Heim, U. Eriksson, S. Marsch, L. Terracciano, and S. Krahenbuhl Fulminant Liver Failure Associated with Clarithromycin Ann. Pharmacother., January 1, 2003; 37(1): 57 - 60. [Abstract] [Full Text] [PDF]

				J. Kajita, K. Inano, E. Fuse, T. Kuwabara, and H. Kobayashi Effects of Olopatadine, a New Antiallergic Agent, on Human Liver Microsomal Cytochrome P450 Activities Drug Metab. Dispos., December 1, 2002; 30(12): 1504 - 1511. [Abstract] [Full Text] [PDF]

				Z.-Q. Liu, B. Zhu, Y.-F. Tan, Z.-R. Tan, L.-S. Wang, S.-L. Huang, Y. Shu, and H.-H. Zhou O-Dealkylation of Fluoxetine in Relation to CYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 105 - 111. [Abstract] [Full Text] [PDF]

				M.-S. Baek, J.-Y. Kim, S.-W. Myung, Y. H. Yim, J.-H. Jeong, and D.-H. Kim Metabolism of Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) by Human Liver Microsomes: Characterization of Metabolic Pathways and of Cytochrome P450 Isoforms Involved Drug Metab. Dispos., April 1, 2001; 29(4): 381 - 388. [Abstract] [Full Text]

				Y. Shu, L.-S. Wang, Z.-H. Xu, N. He, W.-M. Xiao, W. Wang, S.-L. Huang, and H.-H. Zhou 5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 844 - 851. [Abstract] [Full Text]

				K. Yamano, K. Yamamoto, H. Kotaki, S. Takedomi, H. Matsuo, Y. Sawada, and T. Iga Quantitative Prediction of Metabolic Inhibition of Midazolam by Erythromycin, Diltiazem, and Verapamil in Rats: Implication of Concentrative Uptake of Inhibitors into Liver J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1118 - 1126. [Abstract] [Full Text]

				T. Hashizume, M. Mise, Y. Terauchi, L. O, T. Fujii, H. Miyazaki, and T. Inaba N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450 Drug Metab. Dispos., June 1, 1998; 26(6): 566 - 571. [Abstract] [Full Text]

				S. S. Surapaneni, M. P. Clay, L. A. Spangle, J. W. Paschal, and T. D. Lindstrom In Vitro Biotransformation and Identification of Human Cytochrome P450 Isozyme-Dependent Metabolism of Tazofelone Drug Metab. Dispos., December 1, 1997; 25(12): 1383 - 1388. [Abstract] [Full Text]